ATE356149T1 - Bispezifische antikörper gegen cd19 und cd16 und deren verwendung - Google Patents
Bispezifische antikörper gegen cd19 und cd16 und deren verwendungInfo
- Publication number
- ATE356149T1 ATE356149T1 AT01127061T AT01127061T ATE356149T1 AT E356149 T1 ATE356149 T1 AT E356149T1 AT 01127061 T AT01127061 T AT 01127061T AT 01127061 T AT01127061 T AT 01127061T AT E356149 T1 ATE356149 T1 AT E356149T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- polynucleotides
- vectors
- human
- antibodies against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01127061A EP1314741B1 (de) | 2001-11-14 | 2001-11-14 | Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE356149T1 true ATE356149T1 (de) | 2007-03-15 |
Family
ID=8179236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01127061T ATE356149T1 (de) | 2001-11-14 | 2001-11-14 | Bispezifische antikörper gegen cd19 und cd16 und deren verwendung |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050089519A1 (de) |
| EP (1) | EP1314741B1 (de) |
| JP (1) | JP4373788B2 (de) |
| AT (1) | ATE356149T1 (de) |
| AU (1) | AU2002356601A1 (de) |
| DE (1) | DE60127143T2 (de) |
| ES (1) | ES2283368T3 (de) |
| WO (1) | WO2003048209A1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1354600A1 (de) * | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antikörperkombination verwendbar für Tumortherapie |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| AU2006272555B2 (en) | 2005-07-25 | 2012-03-08 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| RS53263B (sr) | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| DK1903115T3 (da) * | 2006-09-22 | 2011-05-23 | Wacker Chemie Ag | Fremgangsmåde til fermentativ fremstilling af antistoffer |
| EP2014680A1 (de) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Rekombinante, einkettige, trivalente trispezifische oder bispezifische Antikörperderivate |
| DE102007041834A1 (de) * | 2007-09-03 | 2009-03-05 | Siemens Ag | Arzneimittel zur Behandlung eines Karzinoms |
| NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP3974453A3 (de) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen |
| WO2012076190A1 (en) * | 2010-12-10 | 2012-06-14 | Merck Patent Gmbh | Bispecific aptamers mediating tumour cell lysis |
| EP2729488A4 (de) * | 2011-07-06 | 2015-01-14 | Medimmune Llc | Verfahren zur herstellung multimerer polypeptide |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| EP2762496A1 (de) | 2013-02-05 | 2014-08-06 | EngMab AG | Verfahren zur Auswahl von Antikörpern gegen BCMA |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Bcmaに対する抗体の選択のための方法 |
| EP2789630A1 (de) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispezifische Antikörper gegen CD3e und ROR1 |
| EP3204415B1 (de) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispezifische antikörper gegen cd3epsilon und ror1 |
| US11000603B2 (en) * | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| CA2992797A1 (en) | 2015-08-03 | 2017-02-09 | Engmab Sarl | Monoclonal antibodies against bcma |
| EP3747472B1 (de) | 2015-09-15 | 2024-04-03 | Acerta Pharma B.V. | Therapeutische kombinationen aus einem cd19-inhibitor und einem btk-inhibitor |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| EP3356405B1 (de) * | 2015-10-02 | 2026-07-08 | F. Hoffmann-La Roche AG | Antikörper gegen humanes cd19 mit hoher affinität |
| EP3450460B1 (de) * | 2016-04-29 | 2023-07-12 | Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. | Multispezifisches bindungskonjugat, entsprechende pharmazeutische zusammensetzungen und verwendung |
| CN109689692B (zh) | 2016-06-22 | 2021-11-12 | 本康生物制药(深圳)有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
| US11124577B2 (en) | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| WO2018158349A1 (en) * | 2017-02-28 | 2018-09-07 | Affimed Gmbh | Tandem diabody for cd16a-directed nk-cell engagement |
| US11795226B2 (en) * | 2017-12-12 | 2023-10-24 | Macrogenics, Inc. | Bispecific CD16-binding molecules and their use in the treatment of disease |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2020089437A1 (en) | 2018-10-31 | 2020-05-07 | Engmab Sàrl | Combination therapy |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| WO2020141145A1 (en) | 2018-12-30 | 2020-07-09 | F. Hoffmann-La Roche Ag | Anti-rabbit cd19 antibodies and methods of use |
| RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
| US20240101677A1 (en) | 2021-01-27 | 2024-03-28 | Innovent Biologics (Suzhou) Co., Ltd. | Single-domain antibody against cd16a and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843708A (en) * | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| ATE199392T1 (de) * | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| HUP9900956A2 (hu) * | 1998-04-09 | 2002-04-29 | Aventis Pharma Deutschland Gmbh. | Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk |
| DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
-
2001
- 2001-11-14 EP EP01127061A patent/EP1314741B1/de not_active Expired - Lifetime
- 2001-11-14 DE DE60127143T patent/DE60127143T2/de not_active Expired - Lifetime
- 2001-11-14 AT AT01127061T patent/ATE356149T1/de active
- 2001-11-14 ES ES01127061T patent/ES2283368T3/es not_active Expired - Lifetime
-
2002
- 2002-11-14 WO PCT/EP2002/012776 patent/WO2003048209A1/en not_active Ceased
- 2002-11-14 US US10/495,508 patent/US20050089519A1/en not_active Abandoned
- 2002-11-14 JP JP2003549396A patent/JP4373788B2/ja not_active Expired - Fee Related
- 2002-11-14 AU AU2002356601A patent/AU2002356601A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050089519A1 (en) | 2005-04-28 |
| JP2005517392A (ja) | 2005-06-16 |
| DE60127143T2 (de) | 2007-11-15 |
| EP1314741B1 (de) | 2007-03-07 |
| WO2003048209A1 (en) | 2003-06-12 |
| EP1314741A1 (de) | 2003-05-28 |
| JP4373788B2 (ja) | 2009-11-25 |
| DE60127143D1 (de) | 2007-04-19 |
| ES2283368T3 (es) | 2007-11-01 |
| AU2002356601A1 (en) | 2003-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60127143D1 (de) | Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung | |
| BR0209989A (pt) | Plataformas baseadas em cromossomas | |
| NO20005296D0 (no) | CD19xCD3-spesifikke polypeptider og anvendelser derav | |
| WO2003048334A3 (en) | Immunocytokines with modulated selectivity | |
| NO346167B1 (no) | Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning | |
| WO2007002223A3 (en) | Cd19 antibodies and their uses | |
| ATE517125T1 (de) | ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN | |
| ATE429450T1 (de) | Chimärische dr4 antikörper und ihre verwendung | |
| ATE233813T1 (de) | Veränderte immunglobuline für spezifische fc- epsilon rezeptoren | |
| ATE157990T1 (de) | Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung | |
| DE69905739D1 (de) | Naphthopyrane die in c5-c6 anneliert sind, ihre herstellung sowie sie enthaltende zubereitungen und (co)polymermatrizen | |
| CY1113145T1 (el) | Μορια υποδοχεα θυμικης στρωματικης λεμφοποιητινης και χρησεις αυτων | |
| DK0980429T3 (da) | Human Toll-lignende receptorproteiner, beslægtede reagenser og fremgangsmåder | |
| DE60210413D1 (de) | Zusammensetzungen zur immunisierung sowie deren verwendung | |
| DE602004007257D1 (de) | Hydroxy-diaryl-carbaldehyd- oxim-verbindungen und deren verwendung als oestrogenwirksame substanzen | |
| IL159527A0 (en) | Human dr4 antibodies and uses thereof | |
| DE69724428D1 (de) | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren | |
| WO2005056606A3 (en) | Optimized antibodies that target the epidermal growth factor receptor | |
| BRPI0415361A (pt) | antagonistas do receptor muscarìnico de acetilcolina | |
| WO2006076691A8 (en) | Irta-2 antibodies and their uses | |
| ATE435872T1 (de) | Anti-interleukin-1 rezeptor antikörper und deren verwendung | |
| DE69729307D1 (de) | Cyanidinzusammensetzungen und deren therapeutische und diagnostische verwendungen | |
| ATE393781T1 (de) | Somatostatin analoge, deren radiomarkierte derivate und deren verwendung | |
| DK0939809T3 (da) | TIE-2 receptor-ligand (TIE ligand-4) og dens anvendelse | |
| ATE171473T1 (de) | Humanisierte monoklonale antikörper gegen humanes interleukin - 4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1314741 Country of ref document: EP |